Amedisys (NASDAQ:AMED) Upgraded at BidaskClub
Several other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of Zumiez from a sell rating to a hold rating in a research note on Saturday, June 22nd. Jefferies Financial Group set a $150.00 price objective on shares of Amedisys and gave the stock a buy rating in a research note on Monday, July 8th. Barclays set a €77.00 ($89.53) price objective on shares of HeidelbergCement and gave the stock a buy rating in a research note on Thursday, March 21st. Finally, Raymond James reissued a buy rating and issued a $21.00 price objective on shares of Colfax in a research note on Thursday, May 2nd. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $131.43.
AMED opened at $123.00 on Tuesday. The stock has a market capitalization of $3.94 billion, a PE ratio of 30.98, a price-to-earnings-growth ratio of 1.53 and a beta of 1.34. The company’s fifty day moving average is $117.75. Amedisys has a fifty-two week low of $92.08 and a fifty-two week high of $140.91. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.
In other news, Director Jake L. Netterville sold 1,863 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $118.17, for a total value of $220,150.71. Following the completion of the sale, the director now owns 73,700 shares in the company, valued at approximately $8,709,129. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott G. Ginn sold 4,872 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $118.50, for a total transaction of $577,332.00. The disclosure for this sale can be found here. Insiders sold a total of 45,028 shares of company stock valued at $5,210,707 over the last three months. Corporate insiders own 2.90% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Alpha Quant Advisors LLC lifted its holdings in shares of Amedisys by 137.0% in the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after acquiring an additional 137 shares during the last quarter. Captrust Financial Advisors lifted its holdings in shares of Amedisys by 161.8% in the 4th quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after acquiring an additional 369 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Amedisys by 102.3% in the 1st quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after acquiring an additional 488 shares during the last quarter. National Asset Management Inc. bought a new stake in shares of Amedisys in the 1st quarter worth about $211,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Amedisys in the 1st quarter worth about $213,000. Hedge funds and other institutional investors own 86.30% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Further Reading: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.